Mital Jhaveri: What New Data Reveal About DOACs and Androgen Receptor Inhibitors?
Mital Jhaveri, Clinical Anticoagulation, Heart Failure Pharmacist at NYC HHC Queens Hospital Center, shared on LinkedIn about a recent article by Mary Beth Nierengarten, published in Cancer, adding:
”Drug Interactions in Focus: What New Data Reveal About DOACs and Androgen Receptor Inhibitors
Managing anticoagulation in cancer patients can be complex, particularly due to potential drug-drug interactions that may heighten bleeding or thrombotic risks.
A recent study published in Cancer examined 2,997 patients with prostate cancer who were receiving direct oral anticoagulants (DOACs) in conjunction with androgen receptor pathway inhibitors, including enzalutamide, apalutamide, or abiraterone.
Key findings include:
- No significant increase in thrombosis risk when using enzalutamide or apalutamide alongside DOACs.
- No significant increase in bleeding risk with abiraterone combined with DOACs.
- Real-world evidence supports the safe co-administration of these therapies in appropriately selected patients.
These findings offer valuable reassurance for clinicians making anticoagulation decisions for patients undergoing modern prostate cancer treatments.
They also underscore the importance of considering real-world outcomes alongside theoretical pharmacokinetic concerns.”
Title: New standard of care for patients with asymptomatic brain metastases from melanoma
Author: Mary Beth Nierengarten
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 6, 2026, 17:39Kalyan Roy: Immunomodulation after Blood Transfusion
-
Jun 6, 2026, 17:37Intissar Haddiya: Can Low-Dose Rivaroxaban Improve Cardiovascular Outcomes in Patients with Advanced CKD?
-
Jun 6, 2026, 17:34Stanley Anokye: From Microcytes and Macrocytes to Target Cells
-
Jun 6, 2026, 16:53Leonardo Roever: Can a Simple Cholesterol Ratio Predict Post-Stroke Depression?
-
Jun 6, 2026, 16:21Abdulkader Jamal Eddin: ABO Blood Group, COVID-19 and Early Respiratory Outcomes in Acute PE
-
Jun 6, 2026, 15:26Yuying Zhang: Grateful to Present on CD44 as A Potential Plasma-Independent Alternative to IVIG in ITP
-
Jun 6, 2026, 15:16Don Deyo: Breakthrough Therapy for Post-Stroke Upper Limb Impairment Now Published
-
Jun 6, 2026, 15:14Julianne Chong: Components of Antithrombotic Stewardship Programs from an International Perspective
-
Jun 6, 2026, 15:13Vincent Ten Cate: The Largest Blood-Based EWAS of Atherosclerosis to Date